Who Are These Programs For? Calibrate and GLP-1 Metabolic Health Eligibility Explained

What Kind of Person Is a Metabolic Health Program Actually Built For?

Metabolic health programs that combine GLP-1 receptor agonist therapy with behavioral coaching are built for adults who have struggled to achieve clinically meaningful weight loss through diet and exercise alone and who carry a body mass index that places them in a medically recognized risk category. The FDA-approved labeling for semaglutide 2.4 mg (Wegovy) defines that threshold as a BMI of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related condition [1].

These are not vanity programs. The clinical rationale is grounded in the recognition that obesity is a chronic, relapsing disease driven by neuroendocrine dysregulation, not simply a failure of willpower. The American Association of Clinical Endocrinology's 2023 guidelines state that "obesity is a chronic, treatable disease that requires long-term management strategies addressing its biological underpinnings" [2].

The BMI Threshold: Why 30 and Why 27

A BMI at or above 30 kg/m² is classified as obesity by the CDC and meets the threshold for pharmacotherapy without any additional conditions [3]. The 27 kg/m² threshold exists because research consistently shows that excess adiposity combined with metabolic dysfunction compounds cardiovascular and metabolic risk even before a person reaches the obesity classification.

The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg subcutaneous weekly produced a mean body weight reduction of 14.9% at 68 weeks compared with 2.4% in the placebo group (P<0.001) [4]. Participants in that trial had a mean baseline BMI of 37.9 kg/m², and roughly 44% carried at least one weight-related comorbidity at enrollment.

Comorbidities That Qualify at the Lower BMI Cutoff

For people with a BMI between 27 and 29.9 kg/m², at least one of the following conditions is typically required for program eligibility:

• Type 2 diabetes or prediabetes. The STEP-2 trial (N=1,210) enrolled adults with type 2 diabetes specifically and showed semaglutide 2.4 mg produced 9.6% weight loss versus 3.4% with placebo at 68 weeks [5].
• Hypertension (systolic blood pressure 130 mmHg or higher, or current antihypertensive use).
• Dyslipidemia (elevated LDL, low HDL, or elevated triglycerides meeting ATP III criteria).
• Obstructive sleep apnea confirmed by polysomnography or clinical diagnosis.
• Nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH).
• Cardiovascular disease or established atherosclerosis.

The SELECT trial (N=17,604) published in the New England Journal of Medicine in 2023 found that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with pre-existing cardiovascular disease and overweight or obesity, further broadening the clinical rationale for treatment in this population [6].

Who Is Explicitly Excluded From These Programs?

Not every adult who wants to lose weight qualifies. GLP-1 receptor agonists carry a boxed warning related to a specific thyroid cancer risk, and several other medical and personal circumstances rule out participation.

The Thyroid Cancer Concern

The FDA label for semaglutide, liraglutide, and tirzepatide carries a boxed warning against use in people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [1]. In rodent studies, GLP-1 receptor agonists caused dose- and duration-dependent thyroid C-cell tumors, though the FDA notes that the relevance of those findings to humans has not been established [7].

Anyone with a first-degree relative with confirmed MTC should disclose this during intake screening. Programs following responsible prescribing guidelines will exclude these individuals from GLP-1 therapy outright.

Other Medical Exclusions

Several additional conditions disqualify candidates from most GLP-1-based programs:

• Active or history of pancreatitis. GLP-1 receptor agonists may increase the risk of acute pancreatitis [1].
• Pregnancy or planning pregnancy within the treatment window. Semaglutide carries a Pregnancy Category X-equivalent risk designation and must be discontinued at least two months before a planned pregnancy [8].
• Severe gastroparesis or a history of gastric outlet obstruction. These conditions worsen with GLP-1 therapy because the drug class slows gastric emptying by design.
• End-stage renal disease or severe hepatic impairment, though mild-to-moderate renal impairment does not necessarily exclude candidates.
• Current use of insulin or sulfonylureas without physician-supervised transition planning, due to hypoglycemia risk.
• Active eating disorders, including anorexia nervosa or bulimia nervosa, require specialist care before entering a weight management program.
• Age <18 years. Wegovy has a separate pediatric indication approved in December 2022 for adolescents aged 12 and older with a BMI at or above the 95th percentile [9], but most commercial metabolic telehealth programs currently serve only adults.

The eligibility framework above reflects standard GLP-1 prescribing criteria drawn from FDA labeling and AACE guidelines. HealthRX clinicians apply a structured intake protocol that maps each of these exclusion criteria against patient-reported history and available lab values before any prescription is issued.

What Does the Program Actually Involve?

Understanding who a program is for also means understanding what that person is agreeing to. Metabolic health programs are not prescription-only services. The evidence base for combining pharmacotherapy with behavioral intervention is meaningfully stronger than for either approach alone.

Medication Component

The medication tier typically includes one of the following FDA-approved agents:

• Semaglutide 2.4 mg subcutaneous weekly (Wegovy): Approved June 4, 2021 for chronic weight management [1].
• Liraglutide 3.0 mg subcutaneous daily (Saxenda): Approved December 2014, produces roughly 5.4% greater weight loss than placebo at 56 weeks [10].
• Tirzepatide 5 mg to 15 mg subcutaneous weekly (Zepbound): Approved November 8, 2023; SURMOUNT-1 (N=2,539) showed up to 20.9% mean weight loss at 72 weeks in the highest-dose group [11].

Dosing always follows a titration schedule to minimize gastrointestinal side effects. For semaglutide 2.4 mg, the titration runs over 16 weeks, starting at 0.25 mg weekly and increasing every four weeks.

Behavioral Coaching Component

The American Heart Association's 2021 scientific statement on obesity treatment found that lifestyle intervention combined with pharmacotherapy produced significantly greater and more durable weight loss than pharmacotherapy alone [12]. Structured programs address four behavioral domains:

1. Food quality: Not calorie restriction alone, but dietary pattern changes emphasizing whole foods, protein adequacy, and limiting ultra-processed food intake.
2. Sleep: Chronic short sleep duration is associated with a 55% higher obesity risk in adults, per a meta-analysis of 30 cohort studies [13].
3. Exercise: Both resistance and aerobic activity help preserve lean mass during GLP-1-induced weight loss, which is a clinically relevant concern since these medications reduce both fat and muscle mass.
4. Emotional health: Stress dysregulation elevates cortisol, which promotes visceral fat accumulation. Behavioral support addresses this directly.

Lab Work and Monitoring

Responsible programs require baseline labs before initiating therapy and repeat labs at intervals throughout treatment. Standard baseline panels include:

• Comprehensive metabolic panel (CMP)
• Lipid panel
• Hemoglobin A1c
• Thyroid-stimulating hormone (TSH)
• Complete blood count (CBC)

TSH screening before program entry is especially relevant for people with undiagnosed hypothyroidism, which mimics and compounds the metabolic dysfunction that drives weight gain. The American Thyroid Association notes that overt hypothyroidism affects roughly 0.3% of the general population and subclinical hypothyroidism affects an additional 4.3% to 8.5% [14].

How Do Thyroid Conditions Affect Eligibility?

Thyroid dysfunction and obesity frequently co-exist, and the interaction between the two matters for program eligibility and outcomes.

Hypothyroidism and Program Participation

Treated, stable hypothyroidism does not disqualify a person from a GLP-1-based metabolic program. A person taking levothyroxine with a TSH in the reference range (typically 0.4 to 4.0 mIU/L) and no signs of under-treatment is generally an appropriate candidate, provided they meet the BMI and comorbidity criteria [14].

Untreated or under-treated hypothyroidism, however, should be addressed before or alongside weight management therapy. Low thyroid hormone levels reduce basal metabolic rate and may blunt the response to GLP-1 therapy by maintaining a physiological state that opposes weight loss. Clinicians should confirm euthyroid status at baseline.

Hyperthyroidism and Program Participation

Active hyperthyroidism is a relative contraindication to GLP-1 therapy in most clinical contexts, not because of a direct drug interaction, but because uncontrolled hyperthyroidism produces its own set of cardiovascular and metabolic instabilities that complicate treatment. A person in stable remission following treatment for Graves' disease or with treated toxic nodular goiter may qualify, subject to physician review.

The MTC/MEN2 Exclusion in Detail

Medullary thyroid carcinoma originates from parafollicular C-cells, which express GLP-1 receptors. The FDA's 2010 approval review for liraglutide required a Thyroid REMS program, later discontinued, and post-marketing surveillance has not established a causal link between GLP-1 use and human MTC [7]. The boxed warning remains because the theoretical risk has not been ruled out, and people with MEN2 carry a near-100% lifetime risk of MTC [15]. Programs must screen for this history at intake.

Age, Sex, and Demographic Considerations

Age-Related Eligibility

Most commercial metabolic telehealth programs serve adults aged 18 to 75. Adults above 75 are not automatically excluded, but prescribing clinicians exercise additional caution given the higher baseline prevalence of renal impairment, sarcopenia, and polypharmacy in that cohort. The clinical priority in adults over 75 may shift from weight reduction to metabolic stabilization and functional preservation.

Sex and Hormonal Status

Both men and women qualify for these programs at the same BMI thresholds. Women in perimenopause or postmenopause may find that hormonal shifts have accelerated visceral fat accumulation even without major changes in diet or activity. The Endocrine Society's 2022 guidelines on obesity management note that menopause-associated weight gain is concentrated in the abdominal region and is independently associated with cardiovascular risk [16].

Men with hypogonadism, identified by a total testosterone below 300 ng/dL, also show higher rates of visceral adiposity and insulin resistance [17]. Addressing low testosterone alongside GLP-1 therapy may improve metabolic outcomes, though these are managed as separate clinical concerns.

Racial and Ethnic Considerations in BMI Thresholds

Standard BMI cutoffs may underestimate metabolic risk in certain ethnic groups. The American Diabetes Association's Standards of Care note that Asian American individuals may meet criteria for pharmacotherapy at a BMI of 23 to 27.4 kg/m² given the higher prevalence of metabolic syndrome at lower BMI values in this population [18]. Clinicians at programs that follow the ADA's updated 2023 standards should apply ethnicity-adjusted thresholds during intake.

What Happens at Intake and How Is Eligibility Confirmed?

The intake process for a legitimate metabolic health program involves several steps that go beyond a simple questionnaire.

Initial Health History Review

Candidates complete a structured medical history covering current medications, prior diagnoses, surgical history (bariatric surgery history affects GLP-1 candidacy), and family history relevant to MTC and MEN2. This review should be conducted or reviewed by a licensed clinician, not an algorithm alone.

Lab Submission or Ordering

Programs either require candidates to submit recent lab work (typically within 90 days) or arrange for labs through a partner network before the first prescription is written. The TSH value, A1c, and comprehensive metabolic panel are the three results most directly relevant to determining both eligibility and starting dose strategy.

Physician or NP/PA Consultation

A synchronous or asynchronous consultation with a physician, nurse practitioner, or physician assistant precedes any prescription. This consultation confirms the intake data, addresses candidate questions about side effects and expectations, and documents the clinical rationale for treatment in the patient record.

Ongoing Eligibility

Eligibility is not a one-time determination. Programs that follow evidence-based practices reassess metabolic markers at 3 months, 6 months, and 12 months. A candidate who loses significant weight and resolves their qualifying comorbidity may technically fall below the 27 kg/m² threshold with resolved hypertension, which becomes a clinical discussion point about continuing versus tapering therapy.

Realistic Expectations for Program Participants

Being eligible for a program does not guarantee any specific outcome. Weight loss response to GLP-1 therapy is variable. In STEP-1, roughly 86% of semaglutide-treated participants lost at least 5% of body weight, 69% lost at least 10%, and 50.5% lost at least 15% [4]. A meaningful minority, approximately 14%, lost less than 5%.

Non-responders at 16 weeks, defined as those who have not lost at least 5% of baseline body weight on a stable dose, should prompt a clinical reassessment of diagnosis, adherence, dose adequacy, and possible medication change.

Side effects are common, particularly in the early weeks. In STEP-1, 74.2% of semaglutide participants reported gastrointestinal adverse events versus 47.9% in the placebo group [4]. Nausea was the most common, reported by 44.2% of the semaglutide group. Most side effects are transient and resolve within four to eight weeks of reaching a stable dose.

How HealthRX Evaluates Candidate Fit

HealthRX clinicians use a structured eligibility checklist that maps FDA labeling criteria, AACE 2023 guidelines, and ADA 2023 standards against each candidate's intake data. Candidates who do not meet the primary BMI threshold but present with a BMI of 25 to 26.9 kg/m² and multiple metabolic risk factors are reviewed case by case by a board-certified physician before any determination is made.

The program is not a fit for people seeking short-term weight loss for an event, people without a qualifying BMI or comorbidity, or people who are unwilling to engage with the behavioral coaching component. The medication produces its best results when the lifestyle domains of food quality, sleep, activity, and stress are addressed alongside it.